| Dr Erin Leigh Grey, MD | |
|
920 Stanton L Young Blvd # 2040, Oklahoma City, OK 73104-5036 | |
| (405) 271-4113 | |
| Not Available |
| Full Name | Dr Erin Leigh Grey |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Neurology |
| Location | 920 Stanton L Young Blvd # 2040, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134717515 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 39386 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erin Leigh Grey, MD 920 Stanton L Young Blvd # 2040, Oklahoma City, OK 73104-5036 Ph: (405) 271-4113 | Dr Erin Leigh Grey, MD 920 Stanton L Young Blvd # 2040, Oklahoma City, OK 73104-5036 Ph: (405) 271-4113 |
News Archive
Today, the Obama Administration is announcing both new regulations to empower consumers to appeal decisions made by their health plans or insurance companies and the availability of resources that will be used to help give consumers more control of their health care decisions. These provisions of the Affordable Care Act will help support and protect consumers and help end some of the worst insurance company abuses.
An analysis of diabetes trials worldwide has found they are not addressing key issues relating to the condition with almost two thirds focusing on drug therapy while only one in ten addresses prevention or behavioural therapies.
Cyclacel Pharmaceuticals, Inc., today announced that it has opened enrollment of the SEAMLESS pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
For about a decade, scientists have recognized that many cases of hereditary breast cancer result from a mutation of a specific gene called BRCA1, which, in its normal state, helps keep tumor formation in check. About five to 10 percent of breast cancer cases are linked to genetic miscues, about half of which are linked to BRCA1.
› Verified 3 days ago
Lindsay Horn, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1140 N Hudson Ave, Oklahoma City, OK 73103 Phone: 405-858-2800 | |
Adil Tumbi, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 920 Sl Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-5251 | |
Matthew Michael Ryan, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 800 N W 9th Street, Suite 100, Oklahoma City, OK 73106 Phone: 405-815-5050 Fax: 405-815-5051 | |
Dr. Meheroz H Rabadi, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 921 Ne 13th St, Oklahoma City, OK 73104 Phone: 405-456-1000 Fax: 405-456-1504 | |
Willis Holloway Jr., M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 6613 N Meridian Ave, Oklahoma City, OK 73116 Phone: 405-603-8450 Fax: 405-603-8455 | |
Chauncey Atterberry, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 921 Ne 13th St, Oklahoma City, OK 73104 Phone: 405-456-1000 | |
Ethan D Lindsey, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1117 Nw 50th St, Oklahoma City, OK 73118 Phone: 405-842-4435 Fax: 405-842-2846 |